<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The heart is frequently afflicted in <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In severe cases, cardiac lesion may directly result in <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Over the years, pharmacological and/or surgical interventions have been the mainstay to alleviate cardiac symptoms in <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Although these traditional modalities remain useful, the emerging field of gene therapy has now provided an unprecedented opportunity to transform our <z:e sem="disease" ids="C0233629" disease_type="Mental or Behavioral Dysfunction" abbrv="">thinking</z:e>/approach in the treatment of dystrophic <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In fact, the premise is already in place for genetic correction </plain></SENT>
<SENT sid="5" pm="."><plain>Gene mutations have been identified and animal models are available for several types of <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Most importantly, innovative strategies have been developed to effectively deliver therapeutic genes to the heart </plain></SENT>
<SENT sid="7" pm="."><plain>Dystrophin-deficient Duchenne <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> is associated with Duchenne <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> (DMD), the most common lethal <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Considering its high incidence, there has been a considerable interest and significant input in the development of Duchenne <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> gene therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Using Duchenne <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> as an example, here we illustrate the struggles and successes experienced in the burgeoning field of dystrophic <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> gene therapy </plain></SENT>
<SENT sid="10" pm="."><plain>In light of abundant and highly promising data with the adeno-associated virus (AAV) vector, we have specially emphasized on AAV-mediated gene therapy </plain></SENT>
<SENT sid="11" pm="."><plain>Besides DMD, we have also discussed gene therapy for treating <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e> in other <z:hpo ids='HP_0003560'>muscular dystrophies</z:hpo> such as <z:hpo ids='HP_0006785'>limb-girdle muscular dystrophy</z:hpo> </plain></SENT>
</text></document>